Modified TNF as a capture ligand
AssigneeImmunicom, Inc.
InventorsMichael Matho, Steven F. Josephs, Annette Marleau
Life of this patent
Estimating the term…
Abstract
A column is disclosed for removal of sTNF-R2 from a body fluid. The column has a compartment, an inlet coupled to the compartment and configured to receive the body fluid, and a substrate disposed within the compartment. A capture ligand is coupled to the substrate and has a modified sequence with an amino acid substitution in a reference sequence that includes a portion of a natural TNF sequence. The modified sequence has an affinity for the sTNF-R2 that is greater than an affinity of the reference sequence for the sTNF-R2.
Claims21
A column for removal of a soluble tumor necrosis factor receptor 2 (sTNF-R2) from a body fluid, the column comprising:
- a compartment;
- an inlet coupled to the compartment and configured to receive the body fluid;
- a substrate disposed within the compartment;
- and
- a capture ligand coupled to the substrate and comprising a modified sequence comprising an amino acid substitution in a reference sequence that comprises a portion of a natural tumor necrosis factor (TNF) sequence;
- wherein the reference sequence is SEQ1 (SEQ ID NO:
- 1), and the modified sequence comprises an amino acid substituted at a site selected from a group consisting of sites 105, 221, 222, and 223 of SEQ1 (SEQ ID NO:1) and has an affinity for the sTNF-R2 that is greater than an affinity of the reference sequence for the sTNF-R2.
Dependencies are inferred from the claim text.